Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 2 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 38

TitleReference numberPublishedLast updated
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098
Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 treatments (terminated appraisal)TA1084
Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1023
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1015
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaTA974
Selinexor with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatmentsTA970
Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA968
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitableTA917
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myelomaTA870
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA841
Daratumumab monotherapy for treating relapsed and refractory multiple myelomaTA783
Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal)TA771
Daratumumab in combination for untreated multiple myeloma when a stem cell transplant is suitableTA763
Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA726
Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA727
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Carfilzomib for previously treated multiple myelomaTA657
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myelomaTA658
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal)TA634
Pomalidomide with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)TA602

Results per page

  1. 10
  2. 25
  3. 50
  4. All